The Phase 1 clinical trial program of MK-0354 included two randomized, double-blind, placebo-controlled studies to assess the safety, tolerability and pharmacokinetics of MK-0354 in healthy volunteers. HDL-cholesterol,, MK-0354 was generally well tolerated at all dose levels. ‘We are pleased with Merck’s decision to push forward MK-0354,’said Jack Lief, Arena ‘s President and CEO. ‘We look forward to the Phase 2 results and the continuous development of the program. ‘ ‘Merck is with the progress of this program to date ‘stated Kathleen Metters, Senior Vice President, Basic Research, Merck Research Laboratories. ‘This is another example by the commitment of Merck to rapidly develop new therapies for the treatment of atherosclerosis.
Arena Pharmaceuticals and Arena are registered registered service marks of the company. Such forward-looking service mark of the company. APD is an abbreviation for Arena Pharmaceuticals Development.Preservative free 84 % of British pharmacists Would Like abandonment preservatives-Free medicinal.
MeadWestvaco Corp. Today announced results out an online survey conducted 100 pharmacist in which UK1 and with regard to their preference for dispensing preservative-free nasal medicines The poll showed that 67 per cent of British chemist have a preference for dispensing a preserving agent – prescription medicines. This %age rose significantly to 84 % after the advantages of preservative-free medication were examined with these Apotheker.
In spite treated with a combination of surgery, radiation and medications the survival rate on patients is not dramatic improved significantly during the last decades. It did previously shown to which protein AIMP2 acted as a tumor suppressor through interaction with others oncosuppressor, however, was that AIMP2 was deed pathologically of human cancer disconnected definitely proved. This research discovered that a variation of AIMP2 is hard expressed in human lung cancer cells.